Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Calando Pharmaceuticals to Present at 19th Annual Oppenheimer Healthcare Conference on November 4, 2008

Abstract:
Calando Pharmaceuticals, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that its CEO, Dr. James Hamilton, will present at the 19th Annual Oppenheimer Healthcare Conference on Tuesday, November 4, 2008 at 11:00am ET. The conference is being held at the Waldorf Astoria Hotel in New York City. Dr. Hamilton's presentation will discuss Calando's proprietary delivery systems for siRNA and small molecule drugs and Calando's clinical program for its two lead compounds, CALAA-01 and IT-101.

Calando Pharmaceuticals to Present at 19th Annual Oppenheimer Healthcare Conference on November 4, 2008

PASADENA, CA | Posted on November 3rd, 2008

CALAA-01, currently undergoing a Phase I clinical trial, is believed to be the first siRNA therapeutic to enter the oncology clinic. To our knowledge, it is also the first systemically delivered siRNA therapeutic formulated with a targeted delivery system. Calando's RONDEL™ delivery system was developed to address the long-standing obstacle of effective delivery and targeting for this potentially revolutionary new class of pharmaceuticals. CALAA-01 is a targeted nanoparticle comprised of a patented, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target and the RONDEL system.

IT-101, Calando's lead candidate delivering a small molecule drug, began clinical trials in 2006. IT-101 demonstrated safety and favorable pharmacokinetic properties in Phase I clinical trials and is currently undergoing a Phase II clinical trial. IT-101 is a conjugate of Cyclosert™, Calando's proprietary delivery system for small molecule drugs, and camptothecin. Both RONDEL™ and Cyclosert™ utilize modified cyclodextrin molecules to create an entirely new class of drug delivery materials, which Calando believes have the ability to solve many of the deficiencies observed in therapeutic product candidates.

Forward-Looking Statements

This news release, and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on Calando's management current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, among others: the risk that CALAA-01 or IT-101 may appear promising in early research and clinical trials but may not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risks that the regulatory approvals may not be obtained, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; and risks associated with our ability to protect our intellectual property and raise the necessary financing to fund our operations and research activities. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

####

For more information, please click here

Contacts:
Calando Pharmaceuticals, Inc.
James C. Hamilton M.D.
626-683-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Reversible Writing with Light: Self-assembling nanoparticles take their cues from their surroundings September 3rd, 2015

For 2-D boron, it's all about that base: Rice University theorists show flat boron form would depend on metal substrates September 2nd, 2015

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Nanostart AG: First-half figures 2015 published and new supervisory board elected : Publication of first-half figures 2015 - Shareholders' meeting elected new supervisory board August 22nd, 2015

Harris & Harris Group Portfolio Company, AgBiome, Secures $34.5 Million Series B Financing Led By Bill and Melinda Gates Foundation August 20th, 2015

Harris & Harris Group Reports Financial Statements as of June 30, 2015, and Announces a Stock Repurchase Program August 10th, 2015

Harris & Harris Group Portfolio Company, HZO, Announces Partnerships with Dell and Motorola August 1st, 2015

Nanomedicine

Reversible Writing with Light: Self-assembling nanoparticles take their cues from their surroundings September 3rd, 2015

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Using DNA origami to build nanodevices of the future September 1st, 2015

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Announcements

Reversible Writing with Light: Self-assembling nanoparticles take their cues from their surroundings September 3rd, 2015

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

Events/Classes

STMicroelectronics Keynotes on the Next MEMS Wave at MIG Conference Asia September 2nd, 2015

JEOL Introduces New Best-in-Class Field Emission SEM September 2nd, 2015

TCL and QD Vision Demonstrate the Future of Wide Color Gamut Television at IFA: Color IQ Based Display is the First Commercially-Branded Television to Present Over 90% of ITU Rec. 2020 Color Gamut September 2nd, 2015

Nanometrics to Participate in the Citi 2015 Global Technology Conference August 26th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic